Body
SAN ANTONIO, TX - Results from NRG Oncology's BR005 study show that breast-conserving treatment without surgery cannot be recommended, based on the study criteria of clinical complete response, radiological complete response (rCR)/near rCR, and negative tumor bed biopsies. These findings were presented at the 2019 San Antonio Breast Cancer Symposium, held December 10-14.
(SACRAMENTO) -- Allison Brashear, Dean of the UC Davis School of Medicine, is working to save the future workforce of neurology and to reduce the gender gap in the medical specialty.
More trained neurologists are needed to meet the demand for care in the U.S. More trained neurologists are needed to meet the demand for care in the U.S.
Researchers from the University of Adelaide have made significant advances in developing a novel vaccine against Zika virus, which could potentially lead to global elimination of the disease.
The virology team, led by Professor Eric Gowans and Dr Branka Grubor-Bauk - based at the Basil Hetzel Institute for Translational Health Research and supported by The Hospital Research Foundation - has developed a vaccine that prevents Zika infection in pre-clinical models of the disease.
HAMILTON, ON, Dec. 13, 2019 - A team of researchers at McMaster University has developed a self-cleaning surface that can repel all forms of bacteria, preventing the transfer of antibiotic-resistant superbugs and other dangerous bacteria in settings ranging from hospitals to kitchens.
The new plastic surface - a treated form of conventional transparent wrap - can be shrink-wrapped onto door handles, railings, IV stands and other surfaces that can be magnets for bacteria such as MRSA and C. difficile.
Microbes living in the rectum could make a difference to the effectiveness of experimental HIV vaccines, according to researchers at the University of California, Davis. The work is published Dec. 11 in the journal mSphere.
Evidence from human and animal studies with other vaccines suggests that Lactobacillus supplements can boost production of antibodies, while treatment with antibiotics can hamper beneficial immune responses, said Smita Iyer, assistant professor at the UC Davis Center for Immunology and Infectious Diseases and School of Veterinary Medicine.
TAMPA, Fla. - Precision medicine with targeted therapies has led to improved treatment options and patient outcomes. These approaches were developed by studying tumors grown in laboratories and patient samples obtained before and during their treatment. However, there is often a limited supply of patient samples to adequately study, and the samples that exist do not always tell the complete genetic story of how the patient responded to specific drugs and the reasons why they failed treatment.
Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC). Results of the trials STARTRK-1 (NCT02097810), STARTRK-2 (NCT02568267), and ALKA, show 77 percent response rate to entrectinib in 53 patients with ROS1+ NSCLC, with a median progression-free survival of 19 months and a median duration of response of 24.6 months.
Baby boys who are born small for their gestational age are at increased risk of having fertility problems in adulthood, according to research published today (Friday) in Human Reproduction [1], one of the world's leading reproductive medicine journals.
Is it safe to give ivermectin to pregnant women? In order to answer this question, researchers from the Barcelona Institute for Global Health (ISGlobal), an institution supported by "la Caixa", conducted a systematic review and meta-analysis of studies that reported cases of accidental exposure to the drug among pregnant women. The conclusion of the analysis, published in The Lancet Global Health, is that there is not sufficient evidence to support the safety of ivermectin administration during pregnancy.
If you want to predict which breast cancer patients will most likely stop taking aromatase inhibitors, check out their own responses to the health questions patients commonly answer in cancer clinical trials, according to research findings to be presented Friday, Dec. 13 at the San Antonio Breast Cancer Symposium.
A retrospective study of nearly 9800 women with breast cancer who participated in randomized clinical trials was presented today at the 2019 San Antonio Breast Cancer Symposium. The study found that women with government insurance (Medicaid or Medicare) were much less likely to participate in a clinical trial compared to their privately insured counterparts. The few women with government insurance who did participate in the trials were more likely to stop treatment early and had lower survival.
Incidence rates for hormone receptor positive (HR+) breast cancers are considerably higher in black men than white men, in stark contrast to lower incidence rates of those cancer subtypes in black versus white women. That's according to a new American Cancer Society study that used nationwide data to provide the first report on differences in subtype-specific breast cancer incidence rates between black men and white men. The study appears in JNCI Cancer Spectrum.
COLUMBUS, Ohio - Bans and other policies restricting e-cigarette sales could do more public harm than good, according to a group of public-health, tobacco-policy and ethics experts.
In a piece published online today (Dec. 12, 2019) in the journal Science, the authors, including three public health deans, caution that blanket policies developed in a rush to address two different concerns come with dangerous downsides - most notably the risk of taking away a powerful tool to help smokers quit.
The Queen Mary University of London professor leading an international breast cancer study says anastrozole - rather than tamoxifen - should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.
Four unsolved mysteries around schizophrenia have long plagued the medical community, but a new hypothesis identifying a common link between them and an almost forgotten epidemic of a disease called pellagra could have profound implications for our understanding of psychosis in poorer nations. The new hypothesis has implications for how a subgroup of people with active psychosis could be potentially screened, treated, and cured.